Hydroxyurea, a myelosuppressive agent that has been a standard treatment in sickle cell disease (SCD) for decades, remains effective over the long term in children with the disease, according to a ...

Hydroxyurea remains effective long-term in reducing emergency department visits and hospital days for children living with sickle cell disease (SCD), according to new research published in Blood ...

Children taking hydroxyurea had fewer ER visits and spent fewer days in the hospital compared to kids not taking the drug, researchers reported April 17 in the journal Blood Advances.

Of the 2,147 participants, 1,240 (58%) had used hydroxyurea; of those, the average time on hydroxyurea was 5.1 years, with 304 children aged eight or older on continuous hydroxyurea therapy.

Hydroxyurea remains effective over the long term among children with sickle cell disease, real-world data suggested. The average time on hydroxyurea was 5 years, with many children on the therapy ...

Of the 2,147 participants, 1,240 (58%) had used hydroxyurea; of those, the average time on hydroxyurea was 5.1 years, with 304 children aged eight or older on continuous hydroxyurea therapy.